Tempest Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew Angel
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7000 Shoreline Court Brisbane CA United States of America 94080
- IPO Date
- Nov 12, 2012
- CIK
- 0001544227
- Website
- tempesttx.com
- Similar Companies
- Business
- Tempest Therapeutics, Inc. Tempest Therapeutics, Inc. (Nasdaq: TPST) is a clinical-stage biotechnology company focused on developing targeted and immune-mediated small molecule therapeutics for cancer treatment. The company advances a pipeline of oral product candidates including amezalpat (TPST-1120), a selective PPARα antagonist for hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and cholangiocarcinoma (CCA); TPST-1495, a dual EP2/EP4 prostaglandin E2 receptor antagonist for solid tumors and familial adenomatous polyposis (FAP); and TREX-1, an enzyme modulating innate immune response in tumors. Founded in 2011 and headquartered in Brisbane, California, Tempest operates primarily in the United States with global clinical collaborations; it functions as a subsidiary of Inception Sciences, Inc. and targets oncology markets through direct tumor killing, immune activation, or combined mechanisms. Recent developments include a collaboration with F. Hoffmann-La Roche Ltd for amezalpat's global Phase 1b/2 study in first-line HCC, yielding positive data with a six-month median overall survival improvement versus standard care; FDA Orphan Drug and Fast Track designations for amezalpat in HCC; and a U.S. FDA Study May Proceed letter for TPST-1495's Phase 2 trial in FAP under National Cancer Institute funding. In November 2025, Tempest entered a definitive all-stock agreement to acquire clinical-stage CD19/BCMA dual-CAR T programs (TPST-2003) from Factor Bioscience Inc., expanding its pipeline for extramedullary disease; the deal anticipates runway extension to mid-2027 via preclosing equity financing and Factor investment, with leadership transition to Matt Angel, Ph.D. as President and CEO. Additional 2025 updates encompass a $8.35 million registered direct offering, Q3 financial results showing $7.5 million cash position, and plans for amezalpat's Phase 3-ready pivotal study in first-line HCC pending resources.
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
New Strong Buy Stocks for April 10th
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Matthew Angel Purchases 231,482 Shares of Tempest Therapeutics (NASDAQ:TPST) Stock
Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday
Tempest Therapeutics Announces Up To $6 Million Private Placement
Head-To-Head Review: Shuttle Pharmaceuticals (NASDAQ:SHPH) versus Tempest Therapeutics (NASDAQ:TPST)
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
Tempest Therapeutics (NASDAQ:TPST) Shares Scheduled to Split on Friday, January 30th
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules